Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer’s Disease (AD)

Abstract

Background: Lecanemab is a humanized IgG1 monoclonal antibody with high affinity to Aβ soluble protofibrils. In two clinical studies (phase 2 and phase 3 Clarity AD) in early AD, lecanemab substantially reduced amyloid PET and slowed clinical decline on multiple measures of cognition and function, including CDR‐SB at 18 months.

The paper